Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. plans for hundreds of millions of cheap, fast COVID-19 tests

09/17/2020 | 07:19am EDT
A healthcare professional adds the extraction reagent and a patient specimen to Abbott’s BinaxNOW COVID-19 Ag rapid test card

U.S. manufacturers are sharply increasing production of cheap, fast - but less accurate - COVID-19 tests, aiming for 100 million per month by year end that will enable schools and workplaces to significantly expand testing.

Manufacturing and government sources tell Reuters that more than half a dozen so-called antigen tests will likely be authorized by the end of October. U.S. regulators in recent months have authorized antigen tests from Abbott Laboratories, Becton Dickinson & Co, Quidel Corp and LumiraDX.

When planned production of the newly authorized tests are combined with previously approved diagnostics, overall monthly U.S. testing capacity will exceed 200 million per month by year end, these sources said.

Makers of the four recently-approved antigen tests have the capacity to make around 40 million per month, but expect to more than double that by year end, according to a Reuters analysis that includes proprietary figures shared by companies.

Unlike the $100 and up molecular diagnostics currently dominating U.S. testing that must be sent to a lab and often take several days for results, antigen tests can cost as little as $5. They can be performed anywhere and produce results in minutes.

That opens the possibility of regular screening at schools and businesses of even asymptomatic people, an important tool for containing future outbreaks, experts said.

"If we could get testing to a scale where everyone you want to test can be tested quickly and cheaply with a quick turnaround time (for results), then you could screen people" before they spread the virus, said Dwayne Breining, director of labs at Northwell Health, New York state's largest hospital system.

Lab-based molecular tests are too hard to make and deploy at that level, he said.

Antigen tests detect certain proteins that are part of the virus from samples taken via nasal or throat swabs, similar to rapid tests for strep throat in a doctor's office.


A lack of testing capacity and little federal coordination early in the pandemic hampered efforts to control spread of the virus that has infected more than 6 million people in the United States.

Still, regulators and health experts are concerned about antigen test reliability. They typically detect the virus around 80% to 90% of the time, below the more than 95% rate of lab-based tests. False negative results raise the likelihood that sick people could unwittingly spread COVID-19.

There is also not enough data to be certain the new tests can detect the virus when infected people are in the early, pre-symptomatic stage, potentially limiting their usefulness.

The U.S. conducted around 25 million tests in August, including lab and antigen tests, according to data from the University of Oxford. Antigen test makers and their suppliers are gearing up for a huge boost.

Tony Lemmo, chief executive of BioDot Inc, which makes dispensers of chemicals used in the tests, says he has recently received orders that would translate into some 500 million tests in the coming months.

The United States could have capacity to conduct 3 million coronavirus tests per day this month, about half of them antigen tests. That could climb to as high as 135 million monthly tests in October, a top health official told a U.S. congressional panel on Wednesday.

European diagnostics companies Roche Holding AG and Quiagen NV have said they will apply for U.S. authorization for their antigen tests.

The National Institutes of Health is working with companies on new tests that will likely add as many as another 30 million tests per month to overall capacity this year, a U.S. official told Reuters. The agency has also provided grants to help testmakers boost manufacturing capacity, including $71 million to Quidel in July.

The U.S. official, who was not authorized to speak publicly, told Reuters that getting to 100 million tests a month by year end could potentially slip by a couple of months because of production challenges.

To ramp up, companies need to hire enough skilled workers and source the paper used in the tests, called nitrocellulose, the official said.

"There's just so much required to go from zero to millions of tests," said Quidel CEO Douglas Bryant, whose company is working with large U.S. universities on daily testing of student athletes.

College football teams in the Big Ten conference will use antigen testing after announcing on Wednesday they would go ahead with games beginning next month.

Nursing homes are using Becton Dickinson's antigen tests to screen residents and staff through a government program.

Even if testmakers succeed in scaling production, capacity will remain tight for some time, as schools, employers and others clamor for tests, executives and officials said.

Quidel has prioritized customer requests for its tests, Bryant said, with healthcare facilities and schools near the top, and industries like tourism further back in line.

(Reporting by Carl O'Donnell; Editing by Caroline Humer and Bill Berkrot)

By Carl O'Donnell

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 0.52% 110.48 Delayed Quote.0.90%
BECTON, DICKINSON AND COMPANY 0.03% 242.72 Delayed Quote.-3.00%
QUIDEL CORPORATION 0.53% 115.38 Delayed Quote.-35.78%
ROCHE HOLDING AG -0.09% 341.7 Delayed Quote.10.58%
06/11QUIDEL  : Receives FDA Emergency Use Authorization for Sophia Q Testing Device
06/11QUIDEL  : Receives Amended Emergency Use Authorization for New Sofia® Q Rapid An..
06/10QUIDEL  : to Present Virtually at Raymond James Human Health Innovation Conferen..
06/04QUIDEL  : JPMorgan Adjusts Quidel's Price Target to $80 From $90, Maintains Unde..
06/02QUIDEL  : Presents at William Blair Conference
06/01INSIDER TRENDS : Insider at Quidel Acquires Stock Via Option/Derivative Security..
05/24QUIDEL  : to Present Virtually at William Blair 41st Annual Growth Stock Confere..
05/24QUIDEL  : COVID-19 Test Gets Health Canada Nod
05/19QUIDEL CORP /DE/  : Submission of Matters to a Vote of Security Holders (form 8-..
05/14QUIDEL  : COVID-19 Home Test Now Available for Sale on Amazon
More news
Financials (USD)
Sales 2021 1 488 M - -
Net income 2021 832 M - -
Net cash 2021 947 M - -
P/E ratio 2021 7,01x
Yield 2021 -
Capitalization 4 910 M 4 910 M -
EV / Sales 2021 2,66x
EV / Sales 2022 3,12x
Nbr of Employees 1 370
Free-Float 88,1%
Duration : Period :
Quidel Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUIDEL CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 169,00 $
Last Close Price 115,38 $
Spread / Highest target 157%
Spread / Average Target 46,5%
Spread / Lowest Target -30,7%
EPS Revisions
Managers and Directors
Douglas C. Bryant President, Chief Executive Officer & Director
Randall J. Steward Chief Financial & Accounting Officer
Kenneth F. Buechler Chairman
Werner Kroll Senior Vice President-Research & Development
Karen C. Gibson SVP-Information Systems & Business Transformation
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA, INC.22.20%66 163